or
forgot password

EGFR-tested Non-Small-Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer: Demographics, Treatment and Outcome Characteristics of Patient Cases in a Community-Based Setting


N/A
N/A
N/A
Open (Enrolling)
Both
Non Small Cell Lung Cancer

Thank you

Trial Information

EGFR-tested Non-Small-Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer: Demographics, Treatment and Outcome Characteristics of Patient Cases in a Community-Based Setting


Inclusion Criteria:



- Patients must have had NSCLC.

- Patients must have received erlotinib (single-agent) for six months or longer for
NSCLC in the second/third line setting or as maintenance therapy.

- Patients must have tissue available for EGFR-mutation status testing (if not
previously performed) or EGFR-mutation status test results available.

- Patients must have tissue available for exploratory genetic analysis.

- Patients must have all clinical information, treatment response data and outcomes
data available for review.

- Patients must be deceased.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Retrospective

Outcome Measure:

demographics

Outcome Description:

To describe patient demographic characteristics of patients with erlotinib (single-agent) treatment duration of six months or longer, including patients who are EGFR-wt. Demographic characterics include age, race,ethnicity, date of initial diagnosis, age at initial diagnosis, location of biopsy at diagnosis, extent of disease with description and location of metastatic sites, histology,and smoking history.

Outcome Time Frame:

24 months

Safety Issue:

No

Principal Investigator

David R Spigel, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Sarah Cannon Research Institute

Authority:

United States: Institutional Review Board

Study ID:

SCRI OUTCOMES 13

NCT ID:

NCT01522833

Start Date:

October 2012

Completion Date:

October 2014

Related Keywords:

  • Non Small Cell Lung Cancer
  • NSLCL
  • Erlotinib
  • Tarceva
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location
Tennessee Oncology, PLLC Clarksville, Tennessee  37043